Literature DB >> 3170119

The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.

P Y Lee1, H Shao, L A Xu, C K Qu.   

Abstract

Hypotensive and other ocular effects were studied for 24 hr after topical application of prostaglandin F2 alpha as the tromethamine salt (PGF2 alpha) in 45 normotensive human subjects. After baseline intraocular pressure (IOP) measurements, 62.5 micrograms, 125 micrograms and 250 micrograms of PGF2 alpha dissolved in 50 microliter of saline was applied to one eye of 15 subjects for each dose tested. Contralateral control eyes received 50 microliter of saline. As compared with the IOP of the contralateral control eyes, topical application of 62.5 micrograms PGF2 alpha caused a significant IOP reduction at 1-12 hr, with a maximal IOP reduction of 2.2 mm Hg at 2 hr. Treatment with 125 micrograms of PGF2 alpha lowered IOP significantly at 1-21 hr, with a maximal reduction of 3.1 mm Hg at 9 hr. Administration of 250 micrograms PGF2 alpha produced a significant reduction of IOP, which lasted for at least 24 hr. A maximal IOP reduction of 2.9 mm Hg occurred at 7 hr. Pupillary diameter was not altered. Aqueous flare and anterior chamber cellular response were not seen in any of the eyes of the subjects at any time after topical application of 62.5-250 micrograms PGF2 alpha. The drug caused side effects consisting of reddened skin of lower lid, ocular irritation, conjunctival hyperemia and headache.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170119

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

2.  The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.

Authors:  R F Wang; C B Camras; S M Podos; K W Lee; K C Bhuyan; D K Bhuyan
Journal:  Trans Am Ophthalmol Soc       Date:  1989

Review 3.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

5.  Latanoprost--a promising new glaucoma drug.

Authors:  S Nagasubramanian
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

Review 6.  New developments in the drug treatment of glaucoma.

Authors:  L M Hurvitz; P L Kaufman; A L Robin; R N Weinreb; K Crawford; B Shaw
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

7.  Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK.

Authors:  Eugénie Goupil; Veronica Wisehart; Etienne Khoury; Brandon Zimmerman; Sahar Jaffal; Terence E Hébert; Stéphane A Laporte
Journal:  Mol Endocrinol       Date:  2012-05-25

8.  Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments.

Authors:  Cindy K Bahler; Kyle G Howell; Cheryl R Hann; Michael P Fautsch; Douglas H Johnson
Journal:  Am J Ophthalmol       Date:  2007-11-07       Impact factor: 5.258

9.  Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans.

Authors:  M Nakajima; Y Goh; I Azuma; O Hayaishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

10.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.